4.7 Article

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial

期刊

ANNALS OF THE RHEUMATIC DISEASES
卷 77, 期 5, 页码 699-705

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2017-212377

关键词

-

资金

  1. UCB Pharma

向作者/读者索取更多资源

Objectives To report 4-year imaging outcomes in the RAPID-axSpA (NCT01087762) study of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), treated with certolizumab pegol (CZP). Methods T his phase III, randomised trial was placebo-controlled and double-blind to week 24, dose-blind to week 48 and open-label to week 204. Patients fulfilling the Assessment of Spondyloarthritis International Society (ASAS) axSpA criteria with active disease were stratified (AS/nr-axSpA) according to the modified New York (mNY) criteria at randomisation. Spinal radiographs were assessed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). MRI inflammation used the Spondyloarthritis Research Consortium of Canada (SPARCC) score for sacroiliac joints (SIJ) and the Berlin spinal score (remission defined as SPARCC < 2 and Berlin <= 2, respectively). Results MRI improvements from baseline (BL) to week 12 were maintained to week 204 (SPARCC BL: AS=8.5, nr-axSpA=7.5; SPARCC week 204: AS=1.3, nr-axSpA=2.4; Berlin BL: AS=7.4, nr-axSpA=4.4; Berlin week 204: AS=2.6, nr-axSpA=1.9). 66.7% of patients with AS and 69.6% of patients with nr-axSpA with BL SPARCC scores =2, and 65.4% of patients with AS and 57.3% of patients with nraxSpA with BL Berlin score > 2, achieved remission at week 204. Mean mSASSS change in AS from BL to week 204 was 0.98 (95% CI 0.34, 1.63); 0.67 (95% CI 0.21,1.13) from BL to week 96; and 0.31 (95% CI 0.02,0.60) from week 96 to week 204. Corresponding nr-axSpA changes were 0.06 (95% CI -0.17,0.28), -0.01 (95% CI -0.19,0.17) and 0.07 (95% CI -0.07,0.20). 4.5% of patients with nraxSpA fulfilled the mNY criteria at week 204, while 4.3% of patients with AS no longer did so. Conclusions In patients with CZP-treated axSpA, rapid decreases in spinal and SIJ MRI inflammation were maintained to week 204. Overall, 4-year spinal progression was low, with less progression during years 2-4 than 0-2. Radiographic SIJ grading changes demonstrated limited progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers

Pedro M. Machado, Martin Schaefer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Loreto Carmona, Kimme L. Hyrich, Philip C. Robinson, Jinoos Yazdany

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Instrument selection for the ASAS core outcome set for axial spondyloarthritis

Victoria Navarro-Compan, Anne Boel, Annelies Boonen, Philip J. Mease, Maxime Dougados, Uta Kiltz, Robert B. M. Landewe, Xenofon Baraliakos, Wilson Bautista-Molano, Praveena Chiowchanwisawakit, Hanne Dagfinrud, Lara Fallon, Marco Garrido-Cumbrera, Lianne Gensler, Bassel Kamal ElZorkany, Nigil Haroon, Yu Heng Kwan, Pedro M. Machado, Walter Maksymowych, Anna Molto, Natasha de Peyrecave, Denis Poddubnyy, Mikhail Protopopov, Sofia Ramiro, In-Ho Song, Salima van Weely, Desiree van der Heijde

Summary: This study aims to define the instruments for the Assessment of SpondyloArthritis international Society-Outcomes Measures in Rheumatology core domain set for axial spondyloarthritis (axSpA). The study selected core outcome instruments through a systematic literature review and assessment of the instruments' psychometric properties. Additionally, the study endorsed additional instruments to enhance the evaluation of axSpA trials.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Anti-CD74 IgA antibodies show diagnostic potential for axial spondyloarthritis but are not associated with microscopic gut inflammation

Ann-Sophie De Craemer, Torsten Witte, Triana Lobaton Ortega, Anne Hoorens, Martine De Vos, Claude Cuvelier, Sebastiaan J. Vastert, Xenofon Baraliakos, Filip Van den Bosch, Dirk Elewaut

Summary: Serum anti-CD74 IgA is a potentially useful diagnostic biomarker for axSpA, but is not associated with gut inflammation or other disease-specific features.

RHEUMATOLOGY (2023)

Article Rheumatology

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study

Robert B. M. Landewe, Denis Poddubnyy, Proton Rahman, Filip E. Van den Bosch, Rebecca Bolce, Soyi Liu Leage, Jeffrey R. Lisse, So Young Park, Lianne Gensler

Summary: In patients with axial spondyloarthritis who flared after withdrawal of IXE therapy, retreatment with open-label IXE can recapture a certain proportion of patients achieving low disease activity (LDA) or inactive disease (ID).

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

Desiree van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A. Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M. Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S. Gensler, Nigil Haroon, Marina Magrey, Walter P. Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip van den Bosch, Thomas Vaux, Huji Xu

Summary: The BE MOBILE 1 and BE MOBILE 2 trials demonstrated that bimekizumab, a dual IL-17A and IL-17F inhibitor, improved efficacy outcomes in patients with axial spondyloarthritis (axSpA) and was well tolerated. These findings support the use of bimekizumab as a potential treatment option for axSpA.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Robert B. M. Landewe

Summary: This study aimed to update the evidence on the efficacy of DMARDs and provide information for the 2022 update of EULAR recommendations for RA management. A systematic literature review was conducted to investigate the efficacy of cs, b, biosimilar, and tsDMARDs in RA patients. The results showed that csDMARDs combined with short-term glucocorticoids in early RA were as effective as bDMARD+MTX combination therapy. JAK inhibitors were effective in different patient populations. Tapering of DMARDs was feasible for some patients who could maintain low disease activity or achieve remission.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Biotechnology & Applied Microbiology

Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis

Juergen Braun, Uta Kiltz, Xenofon Baraliakos

Summary: This review focuses on two emerging drugs, bimekizumab and filgotinib, for the treatment of axial spondyloarthritis and psoriatic arthritis. Unlike other IL-17 inhibitors, JAK inhibitors are also effective in rheumatoid arthritis. Further research is needed to determine the efficacy of these drugs in the treatment of axial spondyloarthritis and psoriatic arthritis.

EXPERT OPINION ON BIOLOGICAL THERAPY (2023)

Article Engineering, Biomedical

Mechanical behavior of the hippocampus and corpus callosum: An attempt to reconcile ex vivo with in vivo and micro with macro properties

Gergerly Bertalan, Julia Becker, Heiko Tzschaetzsch, Anna Morr, Helge Herthum, Mehrgan Shahryari, Ryan D. Greenhalgh, Jing Guo, Leif Schroeder, Christian Alzheimer, Silvia Budday, Kristian Franze, Juergen Braun, Ingolf Sack

Summary: The mechanical properties of brain tissue are complex and vary depending on species, region, measurement method, and in vivo or ex vivo conditions. Through various methods, we found that brain stiffness shows remarkable consistency across species, in vivo and ex vivo states, and different measurement techniques when considering viscoelastic dispersion properties combining equilibrium and non-equilibrium mechanical elements.

JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS (2023)

Article Medicine, General & Internal

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo- controlled, phase 3 trial (BE OPTIMAL)

Iain B. McInnes, Akihiko Asahina, Laura C. Coates, Robert Landewe, Joseph F. Merola, Christopher Ritchlin, Yoshiya Tanaka, Laure Gossec, Alice B. Gottlieb, Richard B. Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Philip J. Mease

Summary: This study evaluated the efficacy and safety of Bimekizumab in patients with active psoriatic arthritis who were naive to biologic DMARDs. The results showed that Bimekizumab treatment had superior improvements in joint, skin, and radiographic efficacy outcomes compared with placebo, and the safety profile was consistent with previous studies.

LANCET (2023)

Article Medicine, General & Internal

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Joseph F. Merola, Robert Landewe, Iain B. McInnes, Philip J. Mease, Christopher T. Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D. Gladman, Laure Gossec, Alice B. Gottlieb, Diamant Thaci, Richard B. Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates

Summary: This study compared the efficacy and safety of Bimekizumab with placebo in patients with active psoriatic arthritis. The results showed that Bimekizumab treatment led to superior improvements in joint and skin efficacy outcomes compared with placebo. The safety profile of Bimekizumab was consistent with previous studies.

LANCET (2023)

Correction Rheumatology

Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program (Feb, 10.3899/jrheum.221022, 2023)

Atul Deodhar, Denis Poddubnyy, Proton Rahman, Jeorg Ermann, Tetsuya Tomita, Rebeca Bolce, Soyi Liu Leage, Andris Kronbergs, Caroline Johnson, Joana Araujo, Ann Leung, Desiree van der Heijde

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?

Lotte van Ouwerkerk, Patrick Verschueren, Maarten Boers, Paul Emery, Pascal Hendrik Pieter de Jong, Robert B. M. Landewe, Willem Lems, Josef S. Smolen, Tom W. J. Huizinga, Cornelia F. Allaart, Sytske Anne Bergstra

Summary: In patients with rheumatoid arthritis (RA), the use of glucocorticoids (GC) as bridging therapy resulted in a more rapid clinical improvement and fewer changes in medication, but similar long-term GC use compared with patients who did not receive bridging therapy.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Do fatty lesions explain the effect of inflammation on new syndesmophytes in patients with radiographic axial spondyloarthritis? Results from the SIAS cohort and ASSERT trial

Rosalinde Stal, Sofia Ramiro, Desiree van der Heijde, Floris A. van Gaalen, Xenofon Baraliakos, Pedro M. Machado, Manouk de Hooge, Rosaline van den Berg, Monique Reijnierse, Juergen Braun, Robert Landewe, Alexandre Sepriano

Summary: In patients with radiographic axial spondyloarthritis, vertebral corner inflammation can lead to the development of syndesmophytes, but only a small portion of this effect is explained by vertebral corner fat deposition.

RMD OPEN (2023)

Letter Rheumatology

Response to: Correspondence on Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis by Sparks et al

Zachary S. Wallace, Jeffrey A. Sparks, Philip C. Robinson, Pedro M. Machado, Jinoos Yazdany

ANNALS OF THE RHEUMATIC DISEASES (2023)

暂无数据